Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca, HealthCore Launch Outcomes Data Project, Seek Multi-Stakeholder Consortium

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca and HealthCore, WellPoint's clinical outcomes research unit, have begun an evidence-development partnership that will focus on "real world" outcomes data in chronic ailments such as diabetes, cardiovascular disease and dyslipidemia.

You may also be interested in...



Anthem Adds Lilly To Its Real-World Drug Outcomes Research Collaborations

The firms are still working to determine specific drugs or disease states to be studied under a five-year agreement. Speeding research dissemination may also be addressed.

Lilly-Humana Outcomes Research Partnership Has Initial Focus on Diabetes

The research will cover the impact of interventions on outcomes, adherence programs, disease management and pharmacoeconomics.

HealthCore And AstraZeneca Big Data Initiative Pushes Ahead, But Will Lack of Trust Deter Additional Partners?

AstraZeneca and HealthCore, a subsidiary of Wellpoint, are halfway through a four-year agreement to study the effectiveness and economics of marketed drugs using real world evidence. The collaboration is making progress, but reaching some goals has been a challenge, says HealthCore CEO Marcus Wilson

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel